DDrare: Database of Drug Development for Rare Diseases

Searched query = "Multiple system atrophy", "MSA-C", "MSA-P", "Olivopontocerebellar atrophy", "OPCA", "Striatonigral degeneration", "Shy-Drager syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 1) Inosine 5'-monophosphate; 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one; 11C-methylreboxetine; 13N-Ammonia; 18F-Dopa; 18F-Dopamne; AFFITOPE® PD01A + Adjuvant; AFFITOPE® PD03A + Adjuvant; AZD3241; AZD3241 100mg; AZD3241 300mg; AZILECT; AZILECT 1 mg comprimidos; Adjuvant without active component; Ammonia; Ampreloxetine; Ampreloxetine chydrochloride; Ampreloxetine hydrochloride; Angiotensin; Angiotensin-(1-7); Anti-Parkinson medication; Atomexetine; Autologous mesenchymal stem cells; Azilect; BHV-3241; BHV-4157; BIIB101; BOTULINUM TOXIN TYPE A; BQ123; Behavioral: BCI-FIT active querying; Behavioral: BCI-FIT adaptive signal modeling; Behavioral: BCI-FIT language modeling; Behavioral: BCI-FIT multi-modal access; Behavioral: Clinical characteristics of AMS patients; Behavioral: Conservative Measures for Orthostatic Hypotension; Behavioral: MOntreal Cognitive Assessment (MoCA); Blood sampling; Botulinum toxin type A; Bq123; Bydureon; CS10BR05; Captopril; Carbidopa; Carbidopa 200mg oral dose; Carbonate; DMI; DOPS; DaTSCAN™ Ioflupane (123I) Injection; DaTscan; Datscan; Desipramine; Desipramine (DMI); Device: Abdominal compression; Device: Deep Brain Stimulation; Device: sham compression; Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau; Diagnostic Test: Flutemetamol F18 Injection; Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau; Diagnostic Test: [18F]-RO6958948; Domperidone; Droxidopa; EGCG; EGCG as putative neuroprotective agent; Emeramide; Entacapone; Entacapone 400mg oral dose; Exenatide; Exenatide Pen Injector [Bydureon]; FLUOXETINE; Fipamezole; Fipamezole hydrochloride; Fipamezole hydrochloride 30 mg oral disintegrating tablets; Fipamezole hydrochloride 60 mg oral disintegrating tablets; Fipamezole hydrochloride 90 mg oral disintegrating tablets; Fludrocortisone; Flumazenil; Fluoxetine; Fluoxétine; Flutemetamol; Flutemetamol F18; GREEN TEA LEAF; Gold; Green Tea; Green tea leaf; Homeostasis Model Assessment of insulin resistance (HOMA); Hydrogen; IUPAC name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one; IVIg; Inosine; Intranasal Insulin; Intravenous immunoglobulin (IVIg); Intravesical injection of Botulinum A toxin; JP-1730/F01; JP-1730/F02; JP-1730/F03; L-Threo DOPS; LITHIUM CARBONATE; LITIO CARBONATO; Levodopa; Levodopa test; Lithium Carbonate; Lithium carbonate; Losartan; Metoprolol; Metoprolol tartrate 50 mg; Midodrine; Modal; N1,N3-BIS(2-MERCAPTOETHYL) ISOPHTHALAMIDE; NBMI; NT 101; Nebivolol; Nebivolol 5 mg; Nitrogen; Normal saline; Other: Abdominal compression; Other: Brain MRI (magnetic resonance imaging); Other: Sham abdominal compression; PROZAC; Procedure: Brain Magnetic Resonance Imaging (MRI); Procedure: determination of objective and subjective pain threshold; Pseudoephedrine; Pseudoephedrine + 480 ml water; Pseudoephedrine + 50 ml water; RASAGILINA MESILATO; Raclopride; Radiation: H215O PET; Radiation: PET (Positron Emission Tomography) Study; Rasagilina; Rasagiline; Rasagiline mesylate; Rifampicin; Riluzole; Rituximab; SAFINAMIDE; Safinamide; Safinamide Methanesulfonate; Safinamide methanesulfonate; Saline; Sildenafil25 mg; Sirolimus; Sirolimus 2 MG; Sunphenon EGCg; TD-9855; Tea leaf; Tllsh2910; Trimethaphan; Ubiquinol; Verdiperstat; Water; Xadago; Xeomin; [18F]FDOPA; [F-18]PBR06

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02008721 (ClinicalTrials.gov)	January 2014	8/12/2013	Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach	Double-blind, Randomised, Placebo-controlled Parallel Group Study to Investigate the Effect of EGCG Supplementation on Disease Progression of Patients With Multiple System Atrophy (MSA)	Multiple System Atrophy	Drug: EGCG as putative neuroprotective agent;Drug: Placebo	Dr. Johannes Levin	German Center for Neurodegenerative Diseases (DZNE);Deutsche Parkinson Vereinigung;Deutsche Stiftung Neurologie;ParkinsonFonds Deutschland gGmbH	Completed	18 Years	N/A	Both	92	Phase 3	Germany
2	EUCTR2012-000928-18-DE (EUCTR)	21/11/2013	28/06/2013	Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA)	Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA) - Progression Rate of MSA under EGCG Supplementation as anti-Aggregation-Approach	Progression of patients with Multiple System Atrophy (MSA);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Sunphenon EGCg INN or Proposed INN: EGCG Other descriptive name: GREEN TEA LEAF	Hospital of the Ludwig-Maximilians-University of Munich	NULL	Not Recruiting			Female: yes Male: yes	86	Phase 3	Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02008721
(ClinicalTrials.gov)

January 2014

8/12/2013

Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach

Double-blind, Randomised, Placebo-controlled Parallel Group Study to Investigate the Effect of EGCG Supplementation on Disease Progression of Patients With Multiple System Atrophy (MSA)

Multiple System Atrophy

Drug: EGCG as putative neuroprotective agent;Drug: Placebo

Dr. Johannes Levin

German Center for Neurodegenerative Diseases (DZNE);Deutsche Parkinson Vereinigung;Deutsche Stiftung Neurologie;ParkinsonFonds Deutschland gGmbH

Completed

18 Years

N/A

Both

Phase 3

Germany

EUCTR2012-000928-18-DE
(EUCTR)

21/11/2013

28/06/2013

Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA)

Progression of patients with Multiple System Atrophy (MSA);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Sunphenon EGCg
INN or Proposed INN: EGCG
Other descriptive name: GREEN TEA LEAF

Hospital of the Ludwig-Maximilians-University of Munich

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

Germany